A preclinical and clinical rationale for quetiapine in mood syndromes

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1211-1219

  McIntyre, Roger S ^a,b,c   Soczynska, Joanna K ^a,c   Woldeyohannes, Hanna O ^c   Alsuwaidan, Mohammad ^a   Konarski, Jakub Z ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antidepressant; Antipsychotic; Bipolar; Clinical; Depression; Preclinical; Quetiapine

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DESIPRAMINE; DOPAMINE; DRUG METABOLITE; FLUOXETINE; GLUCOCORTICOID; GLUTAMIC ACID; HALOPERIDOL; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N DESALKYLQUETIAPINE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PLACEBO; QUETIAPINE; RITANSERIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

BIPOLAR DEPRESSION; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOCRINE SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MEDLINE; MONOTHERAPY; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; XEROSTOMIA; ANIMAL; DRUG SCREENING;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DRUG EVALUATION, PRECLINICAL; HUMANS; MOOD DISORDERS;

EID: 34250825926     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1211     Document Type: Review

References (85)

1. KELLER MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA (2003) 289(23):3152-3160.
2. TRIVEDI MH, RUSH AJ, WISNIEWSKI SR et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry (2006) 163(1):28-40.
3. LIEBERMAN JA: Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry (2006) 63(10):1069-1072.
4. MCINTYRE RS, KONARSKI JZ: Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry (2004) 66 (Suppl. 3):28-36.
5. LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353(12):1209-1223.
6. PERLIS RH, WELGE JA, VORNIK LA et al.: Atypical antipsychorics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry (2006) 67(4):509-516.
7. SUPPES T, DENNEHY EB, HIRSCHFELD RM et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry (2005) 66(7):870-886.
8. YATHAM LN, KENNEDY SH, O'DONOVAN C et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. (2005) 7(Suppl. 3):5-69.
9. KENNEDY SH, LAM RW, COHEN NL et al.: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry (2001) 46(Suppl.1):38S-58S.
10. BAUNE BT, CALISKAN S, TODDER D: Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum. Psychopharmacol. (2007) 22(1):1-9.
11. BERMAN RM, CHARNEY DS: Models of antidepressant action. J. Clin. Psychiatry (1999) 60(Suppl. 14):16-20.
12. O'NEIL MF, MOORE NA: Animal models of depression: are there any? Hum. Psychopharmacol. (2003) 18(4):239-254.
13. BLIER P, SZABO ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry (2005) 66(Suppl. 8):30-40.
14. DELGADO PL: Depression: the case for a monoamine deficiency. J. Clin. Psychiatry (2000) 61(Suppl. 6):7-11.
15. TAYLOR C, FRICKER AD, DEVI LA et al.: Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal. (2005) 17(5):549-557.
16. YATHAM LN, GOLDSTEIN JM, VIETA E et al.: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry (2005) 66(Suppl. 5):40-48.
17. HOU C, JIA F, LIU Y et al.: CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res. (2006) 1095(1):154-158.
18. 2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry (2004) 55(3):217-224.
19. BAKISH D, LAPIERRE YD, WEINSTEIN R et al.: Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J. Clin. Psychopharmacol. (1993) 13(6):409-414.
20. KAPUR S, SEEMAN P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry (2001) 158(3):360-369.
21. 1A receptor agonism. Brain Res. (2002) 956(2):349-357.
22. 2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomic J. (2006) 6(1):42-51.
23. JENSEN J, MCINTOSH AR, CRAWLEY AP et al.: Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron (2003) 40(6):1251-1257.
24. TARAZI FI, ZHANG K, BALDESSARINI RJ: Olanzapine, quetiapine, and risperidone: long-term effects on monoaminc transporters in rat forebrain. Neurosci. Lett. (2000) 287(2):81-84.
25. STAHL SM, ZHANG L, DAMATARCA C et al.: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J. Clin. Psychiatry (2003) 64 (Suppl. 14):6-17.
26. HOEBEL BG: Brain neurotransmitters in food and drug reward. Am. J. Clin. Nutr. (1985) 42(5 Suppl.):1133-1150.
27. GOLDSTEIN JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc) (1999) 35(3):193-210.
28. MEYER JH, MCNEELY HE, SAGRATI S et al.: Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry (2006) 163(9):1594-602.
29. KALIVAS PW, VOLKOW ND: The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry (2005) 162(8):1403-1413.
30. DIEHL DJ, GERSHON S: The role of dopamine in mood disorders. Compr Psychiatry (1992) 33(2):115-120.
31. NEUMEISTER A, WILLEIT M, PRASCHAK-RIEDER N et al.: Dopamine transporter availability in symptomatic depressed patients with seasonal affectivc disorder and healthy controls. Psychol. Med. (2001) 31(8):1467-1473.
32. DI MASCIO M, DI GIOVANNI G, DI MATTEO V, PRISCO S, ESPOSITO E: Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res. Bull. (1998) 46(6):547-554.
33. LAMMERS CH, DIAZ J, SCHWARTZ JC et al.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry (2000) 5(4):378-388.
34. ICHIKA WA J, ISHII H, BONACCORSO S et al.: 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. (2001) 76(5):1521-1531.
35. GEFVERT O, LUNDBERG T, WIESELGREN IM et al.: D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. (2001) 11(2):105-110.
36. LAMMERS CH, DIAZ J, SCHWARTZ JC et al.: Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry (2000) 5(4):378-388.
37. SZEKERES G, KERI S, JUHASZ A et al.: Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2004) 124(1):1-5.
38. BRUNELLO N, BLIER P, JUDD LL et al.: Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int. Clin. Psychopharmacol. (2003) 18(4):191-202.
39. WESTENBERG HG: Pharmacology of antidepressants: selectivity or multiplicity? J. Clin. Psychiatry (1999) 60 (Suppl. 17):4-8.
40. PIRA L, MONGEAU R, PANI L: The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. (2004) 504(1-2):61-64.
41. GOLDSTEIN JM, CRISTOPH G, GRIMM S et al.: Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. American Psychiatric Association's 160th Annual Meeting. San Diego, California, USA (19-24 May 2007).
42. KRYSTAL JH, SANACORA G, BLUMBERG H et al.: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry (2002) 7(Suppl. 1):S71-S80.
43. PAUL LA, SKOLNICK P: Glutamate and depression: clinical and preclinical studies. Ann. N Y Acad. Sci. (2003) 1003:250-272.
44. GERBER U, GEE CE, BENQUET P: Metabotropic glutamate receptors: intracellular signaling pathways. Curr. Opin. Pharmacol. (2007) 7(1):56-61.
45. PALUCHA A, PILC A: On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol. J. Pharmacol. (2002) 54(6):581-586.
46. ZARATE CA, Jr, SINGH JB, CARLSON PJ et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry (2006) 63(8):856-864.
47. TASCEDDA F, LOVATI E, BLOM JM et al.: Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology (1999) 21(2):211-217.
48. MOMBEREAU C, KAUPMANN K, FROESTL W et al.: Generic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology (2004) 29(6):1050-1062.
49. FATEMI SH, STARY JM, EARLE JA et al.: GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. (2005) 72(2-3):109-122.
50. FATEMI SH, STARY JM, EARLE JA et al.: GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. (2005) 72(2-3):109-122.
51. YAN Z: Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol. Neurobiol. (2002) 26(2-3):203-216.
52. ZINK M, SCHMITT A, MAY B et al.: Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr. Res. (2004) 66(2-3):151-157.
53. YOKOTA K, TATEBAYASHI H, MATSUO T et al.: The effects of neuroleptics on the GABA-induced Cl-current in rat dorsal root ganglion neurons: diffirences between some neuroleptics. Br. J. Pharmacol. (2002) 135(6):1547-1555.
54. MARX CE, VANDOREN MJ, DUNCAN GE et al.: Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology (2003) 28(1):1-13.
55. POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem. (2000) 74(1):21-33.
56. POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem. (2000) 74(1):21-33.
57. DUMAN RS: Pathophysiology of depression: the concept of synaptic plasticity. Eur. Psychiatry (2002) 17(Suppl. 3):306-310.
58. FUMAGALLI F, MOLTENI R, BEDOGNI F et al.: Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport (2004) 15(13):2109-2112.
59. POPOLI M, BRUNELLO N, PEREZ J et al.: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J. Neurochem (2000) 74(1):21-33.
60. MCEWEN BS: Stress and hippocampal plasticity. Annu. Rev. Neurosci. (1999) 22:105-122.
61. HASHIMOTO K, SHIMIZU E, IYO M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. (2004) 45(2):104-114.
62. GONUL AS, AKDENIZ F, TANELI F et al.: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch. Psychiatry Clin. Neurosci. (2005) 255(6):381-386.
63. XU H, QING H, LU W et al.: Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. (2002) 321(1-2):65-68.
64. PARK SW, LEE SK, KIM JM et al.: Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci. Lett. (2006) 402(1-2):25-29.
65. LUO C, XU H, LI XM: Quetiapine reverses the suppression of hippocampal neurogcnesis caused by repeated restraint stress. Brain Res. (2005) 1063(1):32-39.
66. LICINIO J, WONG ML: The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symproms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry (1999) 4(4):317-327.
67. SCHIEPERS OJ, WICHERS MC, MAES M: Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(2):201-217.
68. MUSSELMAN DL, BETAN E, LARSEN H et al.: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol. Psychiatry (2003) 54(3):317-329.
69. CAPURON L, MULLER AH: Cytokines and psychopathology: lessons fiom interferon-α. Biol. Psychiatry (2004) 56(11):819-824.
70. CAPURON L, GUMNICK JF, MUSSELMAN DL et al.: Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 26(5):643-652.
71. KENIS G, MAES M: Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. (2002) 5(4):401-412.
72. KHANZODE SD, DAKHALE GN, KHANZODE SS et al.: Oxidative damage and major depression: the potential antioxidant action of selective scrotonin re-uptake inhibitors. Redox Rep. (2003) 8(6):365-370.
73. ALTSCHULER EL, KAST RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med. Hypotheses (2005) 65(1):65-67.
74. RUSH AJ, GILES DE, SCHLESSER MA et al.: The dexamethasone suppression test in patients with mood disorders. J. Clin. Psychiatry (1996) 57(10):470-484.
75. TARAZI FI, MANG K, BALDESSARINI RJ: Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide (2002) 7(4):297-300.
76. CORYELL W, YOUNG E, CARROLL B: Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortatity in major depressive disorder. Psychiatry Res. (2006) 142(1):99-104.
77. PLOTSKY PM, OWENS MJ, NEMEROFF CB: Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am.
78. BELANOFF JK, ROTHSCHILD AJ, CASSIDY F et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry (2002) 52(5):386-392.
79. YOUNG AH, GALLAGHER P, WATSON S et al.: Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology (2004) 29(8):1538-1545.
80. COHRS S, ROHER C, JORDAN W et al.: The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmarology (Berl) (2006) 185(1):11-18.
81. CALABRESE JR, KECK PE, JR, MACFADDEN W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry (2005) 162(7):1351-1360.
82. THASE ME, MACFADDEN W, WEISLER RH et al.: Efficacy of quedapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J. Clin. Psychopharmacol. (2006) 26(6):600-609.
83. ZARATE CA, Jr:, TOHEN M: Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry (2004) 161(1):169-171.
84. TOHEN M, VIETA F, CALABRESE J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60(11):1079-1088.
85. CORYA SA, ANDERSEN SW, DETKE HC et al.: Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry (2003) 64(11):1349-1356.